ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Soleus Capital Management L.P.

Soleus Capital Management L.P. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 205,294 shares of the specialty pharmaceutical company's stock after selling 63,706 shares during the period. Soleus Capital Management L.P. owned about 0.98% of ANI Pharmaceuticals worth $11,349,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. US Bancorp DE grew its position in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV boosted its stake in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after buying an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $166,000. Rafferty Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $200,000. Finally, Bridgefront Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $204,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Ori Gutwerg sold 881 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president now owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,681 shares of company stock valued at $468,698 in the last quarter. Company insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Stock Down 3.1%

Shares of NASDAQ:ANIP traded down $1.81 during mid-day trading on Thursday, hitting $57.27. 358,437 shares of the company traded hands, compared to its average volume of 301,573. The firm's 50 day simple moving average is $66.76 and its 200 day simple moving average is $60.79. The firm has a market cap of $1.24 billion, a P/E ratio of -104.13 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. During the same quarter last year, the company earned $0.82 earnings per share. ANI Pharmaceuticals's revenue for the quarter was up 43.4% on a year-over-year basis. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ANIP shares. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. Guggenheim reissued a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.